Global Injectable Drugs Market Report: Market Segmentation Based on Product Type & by Region with Forecast 2017-2030

Global Injectable Drugs Market Overview

Drugs which are introduced into body with syringe & needle as a medium is termed as injectable drugs. Among all the approved drugs by Food & Drug Administration (FDA) available in U.S., 97% of medications & vaccines are administered through injections. Top injectable drugs such as remicade, avastin neulasta, rituxan, etc. are most commonly used across the globe. In 2012, over 180,000 units of remicade were available per one million lives worldwide. Nowadays, increasing price of injectable biotech products is a challenge for every commercial player in the United Sates. In 2010, approval of several cancer therapies by FDA has driven the cost of injectable drugs up to 4.0%. However, injectable drugs used for cancer treatment accounted for more than 50.0% of benefits of medical injectable costs. Recent increase in commercial health plans is establishing attractive business opportunities for injectable drugs in Europe and North America region. In 2012, more than 60% of population in the United States received medical benefits, which is extensively raising the demand of injectable drugs in the region. Although, illegal use of injectable drugs is expected to hamper the adoption rate of injectable drugs across the globe. In 2012, Greece and the UK have 3.1% and nearly 10% of per 1000 population who were using injectable drugs illegally. Spain, UK, France and Italy has higher rate of abusing medical drugs as compared to other European countries. Moreover, the U.S. and Canada have nearly 3.0% of population aged above 12 years are illegally using medical injectable drugs. This is one of the major factors which are obstructing the injectable drugs market. However, stringent drugs polices is likely to reduce the illegitimate use of injectable drugs worldwide.

Acquisition and collaboration plays an important role in enabling business opportunities for injectable drugs. In the 2016 year, InvaGen Pharmaceutical was acquired by Cipla for USD 550 million. In October 2016, India based company Piramal announced to buy 5 drugs for pain and anesthetic management from Johnson & Johnson by paying USD 155 million. Piramal holds a significant presence in global generic injectable drug market which valued USD 20 billion in 2016. These acquisitions and partnerships are expected to drive the growth of injectable drugs market during the time period of 2017-2030.

Global Injectable Drugs Market Segmentation

The global injectable drugs market is categorized on the following basis:

Based on Product Type

• Vaccines

• Insulin

• Conventional Therapeutics

• Complex Biologics

Based on Geography

• North America (U.S. & Canada)  {Market Size (USD Billion), Growth Analysis (%) and Opportunity Analysis}

•  Latin America ( Brazil , Mexico & Rest of Latin America)       {Market Size (USD Billion), Growth Analysis (%) and Opportunity Analysis}

• Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE) {Market Size (USD Billion), Growth Analysis (%) and Opportunity Analysis}

• Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia) {Market Size (USD Billion), Growth Analysis (%) and Opportunity Analysis}

• Middle East & Africa (GCC, South Africa, North Africa, RoMEA) {Market Size (USD Billion), Growth Analysis (%) and Opportunity Analysis}

•  Rest of World {Market Size (USD Billion), Growth Analysis (%) and Opportunity Analysis}

Market Size and Forecast (2017-2030)

Global injectable drugs market is anticipated to growing at a CAGR of 8.23% during the forecast period of 2017 to 2030. North America is the dominating region in global injectable drugs market in 2017. Rising number of chronic health issues and increasing number of partnership between medical companies to provide high quality affordable drugs is boosting the demand of injectable drugs in U.S. and Canada. 

Based on segmentation, complex biologics holds the largest share nearly 60.0% of global injectable drugs market in 2017. Increase in number of new drugs rising demand for license approval for biologics and new drugs is accelerating the market of complex biologics segment. Vaccines and insulin segment is expected to witness notable growth with 20.0% and 10.0% share of injectable drugs market over the forecast period.

Asia-Pacific region is expected to be the fastest growing region in injectable drug market over the forecast period. Asia-Pacific region is expected to growing at a CAGR of 10.51 % over the forecast period. Rising health awareness and growing penetration of self injection technology in Japan, Singapore & China is boosting the demand of injectable drugs in the region. Increasing number of diabetes population in emerging economies such as India & China is expected to witness significant growth during the time period of 2017-2030.

Europe was the second largest region for injectable drugs market in 2015, owing to the popularity of self-injectable drug technology in the region. Growing demand of hormone replacement & cancer therapies are driving the adoption rate of injectable drugs in Italy, Germany, the UK, Spain and other European countries. Europe is the leading region in self injection technology due to low rate of penetration of pen injectors in North America region. 

Lack of proper medical facilities, low competition and less stringent regulatory framework related with approval on medical drugs and devices is anticipated to create attractive business opportunities for injectable drugs in Latin America & Middle East & Africa. Latin America & Middle East & Africa together held 7.0% market share in global injectable drug market in 2017. Saudi Arabia, Israel, Mexico, Brazil & Argentina are estimated to gain favorable opportunities for injectable drugs in the forecast years.

Drivers and Challenges to Growth Market

Rise in per capita drug spending, increase in personal disposable income and patient awareness are key factors to drive the growth of global injectable drugs market. Rising number of patients affected with chronic disease such as cancer and diabetes is likely to boost the demand for injectable drugs worldwide. Operational improvement, medical benefits and reimbursement policies are also driving the injectable drugs market.

Risk of re-operation or death, safety concerns of injectable drugs and less patient compliance is restraining the expansion of injectable drugs market.

Covered In This Global Injectable Drugs Market Report 

Market Synopsis

Key Market Players

• Pfizer Inc.

  • Synopsis

  • Business Strategy

  • Product Portfolio

  • SWOT Analysis

• Johnson & Johnson

• Novartis AG

• Merck & Co. Inc.

• Baxter International Inc.

• Sanofi

• GlaxoSmithKline Plc.

• AstraZeneca

• GILEAD SCIENCES, Inc.

• Nova Nordisk A/S

• Sun Pharmaceutical Industries Ltd.

• Teva Pharmaceutical

Market Segmentation

The Global Injectable Drugs Market is segmented as follows:

• By Product Types (Market Size, Demand Analysis and Growth Analysis)

By Regions

• North America (U.S., Canada) {Market Size, Growth Analysis and Adoption Rate}

• Latin America (Argentina, Mexico, Brazil and Rest of Latin America) {Market Size, Growth Analysis and Adoption Rate }

• Europe (Germany, Italy, Spain, France, The U.K., Netherlands, Sweden, Hungary, Russia, Poland, Rest of Europe) {Market Size, Growth Analysis and Adoption Rate }

• Asia-Pacific (China, India, Singapore, Japan, Hong-Kong, Australia, New Zealand, South Korea and Rest of Asia Pacific) {Market Size, Growth Analysis and Adoption Rate }

• Middle East and North Africa (MENA) {Market Size, Growth Analysis and Adoption Rate}

• Rest of World  {Market Size, Growth Analysis and Adoption Rate}

Market Dynamics: Growth Drivers, Restraints and Opportunities

• Risk Factors

• Regional Variations

• Recent Trends and Developments

Key Market Players

• Synopsis

• Business Strategy

• Product Portfolio

• SWOT Analysis

Porter’s Five Force Model

Market Landscape: Competition and Beyond

Market outlook for business players and entry level players to ascertain their business in dynamic ecosystem

Expert Analysis

Concluding Remarks